𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical evaluation of plasma des-γ-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes

✍ Scribed by Akinori Kasahara; Norio Hayashi; Hideyuki Fusamoto; Yoshio Kawada; Yasukiyo Imai; Hideo Yamamoto; Eijiro Hayashi; Toshio Ogihara; Takenobu Kamada

Book ID
112509948
Publisher
Springer US
Year
1993
Tongue
English
Weight
657 KB
Volume
38
Category
Article
ISSN
0163-2116

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Plasma abnormal prothrombin (Des-γ-carbo
Plasma abnormal prothrombin (Des-γ-carboxy prothrombin) as a marker of hepatocellular carcinoma
✍ Shigetoshi Fujiyama; Takafumi Morishita; Osamu Hashiguchi; Tatsuo Sato 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 732 KB

Des-y-carboxy prothrombin [DCP], a protein induced by vitamin K absence or antagonist-I1 and also abbreviated PIVKA-11, was evaluated as a serologic marker for hepatocellular carcinoma (HCC). Its plasma levels were measured by enzyme immunoassay (E-1023) using an anti-DCP monoclonal antibody in 514

Unique clinical characteristics of patie
Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-γ-carboxy prothrombin and low serum α-fetoprotein
✍ Keisuke Hamamura; Yasushi Shiratori; Shuichiro Shiina; Masatoshi Imamura; Shunta 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## BACKGROUND. Although the importance of ␣-fetoprotein (AFP) and des-␥-carboxy prothrombin (DCP) in the clinical treatment of hepatocellular carcinoma (HCC) has been studied extensively, the authors examined the clinical picture of HCC with regard to the state of these two tumor markers. ## METHO